Robert W. Baird initiated coverage on Oculis Holding AG with a new price target
$OCS
Biotechnology: Pharmaceutical Preparations
Health Care
Robert W. Baird initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $58.00